Liquidia Technologies announced that Jason Adair has been named Vice President, Business Development & Strategy. Mr. Adair will be responsible for leading Liquidia's business development activities, including partnering and licensing, in an effort to maximize Company growth through its novel drug delivery, product development and manufacturing capabilities. He will also play a key role in the execution of the Company's long-term commercial strategy to develop its own products.

Before joining Liquidia, Mr. Adair led business development efforts at BioCryst Pharmaceuticals. During his time at BioCryst, he led the commercial launch and subsequent partnering of the company's first FDA approved drug for influenza, provided commercial insight for programs in rare disease and managed alliances with partners in Japan, Korea, Israel and the United Kingdom. Prior to BioCryst, Mr. Adair worked in the field of biologics at MedImmune/AstraZeneca in roles of increasing responsibility in business development, marketing and operations.